Cannabis Wheaton: A Portfolio of Opportunities

Cannabis Wheaton (TSX: CBW.V) (OTC: KWFLF) is a newly traded Canadian cannabis company that has received significant coverage since it started trading due its management team and differentiated strategy.

Although the company is focused on cannabis production, it does not actually produce cannabis. Cannabis Wheaton invests and partners with licensed Canadian medical cannabis companies that are in various stages of the licensing process.

Cannabis Wheaton’s streaming partners include 14 companies in six provinces across Canada. Of these companies, 2 have sales licenses (Broken Coast and Green Relief), 3 have cultivation licenses, 3 have affirmation letters and 6 are advanced pre-affirmation stage applicants. Through these agreements, Cannabis Wheaton has access to 1.3 million square feet of cultivation by 2019.

Beleave: First Streaming Partner to Receive Cultivation License

One of its streaming partners, Beleave (BLEVF) (BE.CN: CSE) issued a corporate update earlier today which reported some significant developments. This comes only days after Beleave was awarded a cultivation license from Health Canada.

Earlier this month, the companies signed an agreement where Cannabis Wheaton will finance a second production facility for Beleave in return for equity in a joint venture company and a production yield allocation from the new facility.

The cultivation license significant a milestone for both Beleave and Cannabis Wheaton. While it is more significant for Beleave, it is first streaming partner to advance in Health Canada’s licensing process. This is a trend that we expect to continue to occur for Cannabis Wheaton’s streaming partners over the coming months.

Artiva: An Early Stage Opportunity

Another holding within Cannabis Wheaton’s portfolio is Artiva, an advanced pre-affirmation stage applicant. The company is a subsidiary of LiveWell which is a leading Canadian cannabis and functional food business.

LiveWell has an attractive business model and it has three distinct divisions. The company is focused on fresh produce though Sole Produce, food manufacturing though Delisse, industrial hemp though O-Hemp, and medicinal cannabis though Artiva.

We are favorable on the company’s partnership with Cannabis Wheaton and believe they will benefit from management’s understanding of the Canadian cannabis industry. Investors interested in learning more about LiveWell can contact them here.

Broken Coast: A High-Quality Holding

One of the most exciting investments in Cannabis Wheaton’s portfolio is Broken Coast Cannabis Ltd., a British Columbia based medical cannabis producer that has established itself as a top providers of high grade cannabis products.

Broken Coast’s clean tech production methods and systems deliver consistent premium cannabis. The company was also recently awarded one of the few 18-month ACMPR licenses, which is a testament to its compliance record.

Broken Coast and its entities will utilize the experience and capital of Cannabis Wheaton to accelerate expansion and scale production in a short period of time. Under the agreement, Broken Coast will source a proposed site to complement its current site. The parties expect the new location to accommodate at least a 100,000 square foot cultivation facility.

Broken Coast will operate the facility in accordance with its industry best practices and the two companies will share the proceeds derived from the output on a 49%/51% basis, 49% of which will be for the benefit of Cannabis Wheaton.

Become a Mushroomstocks Premium Member to learn more!

Important Investor Disclosures

Disclosure. Compensated Affiliate. This report was authored by and is property of StoneBridge Partners. All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report. Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice. Any projections or other information generated by StoneBridge Partners regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results. None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment. This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation. The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals. It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction. Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks. The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission. Please contact a Financial Advisor for professional advice regarding any and all securities investments. This report is intended for informational purposes only. StoneBridge Partners’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners. StoneBridge Partners may receive compensation from the company and/or has a position in the securities mentioned in this report